Truist Securities Reinstates Alkermes (ALKS) Coverage with Buy Rating and $55 Price Target

gurufocus.com · 2026-10-16

On October 16, 2026, Truist Securities resumed coverage of Alkermes PLC (NASDAQ: ALKS) with a Buy rating and set a price target of $55 per share. The firm empha

TickrTrends take: Truist Securities has reinstated coverage of Alkermes with a Buy rating and a $55 price target, suggesting confidence in the company's prospects within the Healthcare sector. This analyst action contrasts with TickrTrends' current assessment that the stock is overvalued, creating a divergence between institutional expectations and the valuation metrics that inform algorithmic analysis. Investors focused on valuation should monitor whether fundamental developments or market conditions shift to reconcile this gap between the analyst's target price and the current overvalued designation.

Read the full story at gurufocus.com →